The tweet was deleted by the author.
But we saved everything 🙂.
CVRx has announced a partnership with Staten Island University Hospital to deliver the hospital's first Barostim implant. This collaboration involved Dr. Kenneth Dulnuan, Dr. Jonathan Schor, Stacey Quinones, MSN, FNP-C, Gresa Bajraktarevic, MS, PA-C, and the clinical team.
The Barostim device introduces a novel therapy option now available to patients, representing a step forward in innovative treatment for challenging cardiovascular conditions. The move underscores growing adoption of device-based therapies in hospital settings.
View post on X Loading...
CVRx previously announced Barostim therapy as an approach targeting the root mechanisms of heart failure. Company executive Philip Adamson discussed his perspective on the evolution of heart failure treatments in a recent medical podcast appearance. These initiatives reflect ongoing developments in CVRx’s heart failure care portfolio.